The REACH solution was designed to bring clinical expertise to patients in urban, rural or underserved areas, particularly for the timely treatment of conditions such as stroke. Numerous peer-reviewed publications document the clinical benefits of "telestroke" as well as the REACH approach to telestroke. Systems using REACH have decreased onset to treatment times to almost 20 minutes faster than the national average.
Expanding Treatment for Acute Ischemic Stroke
Currently, tPA (tissue Plasminogen Activator) is the only FDA approved drug for acute ischemic strokes. Time is of the essence for the effective administration of intravenous tPA. However, intravenous tPA is used infrequently. A common reason cited is inadequate stroke care expertise at rural hospitals. Since the recommendation to administer tPA can only be completed by a stroke specialist – a resource that is often non-existent in rural hospitals – the logistical challenges in stroke treatment are often insurmountable. However, REACH has created the technology and developed the expertise to close the gap.
Using Stroke Networks to Improve Patient Outcomes
A large body of evidence points to the value of stroke networks, i.e. telestroke, as a means of improving stroke patient outcomes. As a result, the American Stroke Association (ASA) has published National Recommendations for the development of Stroke Networks. The REACH telestroke solution is designed to work in support of the ASA recommendations